Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Oracle (ORCL)

Oracle Names Tomislav Mihaljevic, Cleveland Clinic CEO, to Board of Directors

Neutral Impact 2 of 5 leadership Written later

Oracle's board unanimously elected Tomislav Mihaljevic as a director effective immediately, with the election dated May 6, 2026, and announced in a May 12, 2026 press release. The filing says the board was increased to 13 members and that he has not been named to any committee at this time, so the change adds a board member without changing executive leadership.

Key points

  • Board elected Dr. Tomislav Mihaljevic effective May 6, 2026; the board size was increased to 13.
  • Dr. Mihaljevic is CEO and President of Cleveland Clinic, a position he has held since January 2018.
  • He is not currently on any board committee; he will receive restricted stock units on May 31, 2026 that fully vest on the first anniversary of the grant.
  • Directors serve one-year terms and will next stand for election at the annual meeting in November 2026.

The filing

CompanyOracle (ORCL)
Form8-K, current report
Filed with the SECMay 12, 2026, 4:50 PM ET
Accession number0001193125-26-219708

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.